As TERT alterations are common in BRAF V600 mutant melanomas and plays an important role in controlling the apoptosis of cancer cells, combined therapies targeting both BRAF and TERT may potentially improvement the survival of these patients [108]. This evidence concerns the gene BRAF and melanoma.